[Special Stock] 'Celltrion 3 Brothers' Rising Amid Declining Market
[Asia Economy Reporter Geum Bo-ryeong] On the afternoon of the 23rd, Celltrion, Celltrion Pharm, and Celltrion Healthcare, which are scheduled to hold a press conference related to COVID-19 treatment and diagnostic kits, are showing strong performance despite the declining market.
As of 2:38 PM on the same day, Celltrion recorded 175,000 KRW, up 15.08% (23,000 KRW) compared to the previous day. At the same time, Celltrion Healthcare rose 8.01% (5,000 KRW) to 67,400 KRW, and Celltrion Pharm increased 26.39% (9,000 KRW) to 43,100 KRW.
Seojeongjin, Chairman of the Celltrion Group, is known to hold an online press conference after the market closes today regarding the "progress of COVID-19 antibody treatment and diagnostic kit development and the possible timing for human clinical trials."
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
- [Breaking] Prime Minister Kim Minseok: "All Possible Response Measures, Including Emergency Mediation, Will Be Considered If Strike-Related Damages Are Feared"
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
- Is It Really Like an Illness? "I Can't Wait to Go Again"—Over 1 Million Visited in Q1, Now 'Busanbyeong' Takes Hold [K-Holic]
Chairman Seo also announced plans at the first online press conference held on the 12th to develop a COVID-19 treatment within six months and a rapid diagnostic kit within three months, if possible.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
